^
PD-L1 overexpression
|
Soft Tissue Sarcoma
|
PD-L1 overexpression
|
Soft Tissue Sarcoma
|
camrelizumab Sensitive: C4 – Case Studies
Front Oncol - 2 weeks
|
camrelizumab Sensitive: C4 – Case Studies
Front Oncol - 2 weeks
|
ETV6-NTRK3 fusion
|
Soft Tissue Sarcoma
|
ETV6-NTRK3 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: C4 – Case Studies
J Pediatr Hematol Oncol - 3 weeks
|
larotrectinib Sensitive: C4 – Case Studies
J Pediatr Hematol Oncol - 3 weeks
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
olaratumab Sensitive: A1 - Approval
|
olaratumab Sensitive: A1 - Approval
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: A1 - Approval
|
trabectedin Sensitive: A1 - Approval
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
pazopanib Sensitive: A1 - Approval
|
pazopanib Sensitive: A1 - Approval
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
tazemetostat Sensitive: A1 - Approval
|
tazemetostat Sensitive: A1 - Approval
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
doxorubicin hydrochloride Sensitive: A1 - Approval
|
doxorubicin hydrochloride Sensitive: A1 - Approval
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline
|
ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
AIM Sensitive: A2 - Guideline
|
AIM Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Soft Tissue Sarcoma
|
NTRK3 fusion
|
Soft Tissue Sarcoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
GT Sensitive: A2 - Guideline
|
GT Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Soft Tissue Sarcoma
|
NTRK1 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Soft Tissue Sarcoma
|
NTRK3 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
gemcitabine + dacarbazine Sensitive: A2 - Guideline
|
gemcitabine + dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
cediranib Sensitive: A2 - Guideline
|
cediranib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
ALK translocation
|
Soft Tissue Sarcoma
|
ALK translocation
|
Soft Tissue Sarcoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
regorafenib Sensitive: A2 - Guideline
|
regorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
gemcitabine + vinorelbine tartrate Sensitive: A2 - Guideline
|
gemcitabine + vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
MAID Sensitive: A2 - Guideline
|
MAID Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
epirubicin Sensitive: A2 - Guideline
|
epirubicin Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Soft Tissue Sarcoma
|
NTRK1 fusion
|
Soft Tissue Sarcoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
NTRK2 fusion
|
Soft Tissue Sarcoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
doxorubicin hydrochloride + ifosfamide + mesna Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + ifosfamide + mesna Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
AD Sensitive: A2 - Guideline
|
AD Sensitive: A2 - Guideline
|
ALK translocation
|
Soft Tissue Sarcoma
|
ALK translocation
|
Soft Tissue Sarcoma
|
brigatinib Sensitive: A2 - Guideline
|
brigatinib Sensitive: A2 - Guideline
|
ALK translocation
|
Soft Tissue Sarcoma
|
ALK translocation
|
Soft Tissue Sarcoma
|
ceritinib Sensitive: A2 - Guideline
|
ceritinib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
vinorelbine Sensitive: A2 - Guideline
|
vinorelbine Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
SA033 Sensitive: A2 - Guideline
|
SA033 Sensitive: A2 - Guideline
|
MSH3 overexpression
|
Soft Tissue Sarcoma
|
MSH3 overexpression
|
Soft Tissue Sarcoma
|
ifosfamide + epirubicin Resistant: B - Late Trials
|
ifosfamide + epirubicin Resistant: B - Late Trials
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
L-ANN Sensitive: B - Late Trials
|
L-ANN Sensitive: B - Late Trials
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
KIAA1549-BRAF fusion
|
Soft Tissue Sarcoma
|
KIAA1549-BRAF fusion
|
Soft Tissue Sarcoma
|
bevacizumab + sorafenib + temsirolimus Sensitive: C3 – Early Trials
|
bevacizumab + sorafenib + temsirolimus Sensitive: C3 – Early Trials
|
CUL4A overexpression
|
Soft Tissue Sarcoma
|
CUL4A overexpression
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: C3 – Early Trials
|
trabectedin Sensitive: C3 – Early Trials
|
ERCC5 overexpression
|
Soft Tissue Sarcoma
|
ERCC5 overexpression
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: C3 – Early Trials
|
trabectedin Sensitive: C3 – Early Trials
|
ERCC1 overexpression
|
Soft Tissue Sarcoma
|
ERCC1 overexpression
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: C3 – Early Trials
|
trabectedin Sensitive: C3 – Early Trials
|
TAF15-NR4A3 fusion
|
Soft Tissue Sarcoma
|
TAF15-NR4A3 fusion
|
Soft Tissue Sarcoma
|
sunitinib Resistant: C3 – Early Trials
|
sunitinib Resistant: C3 – Early Trials
|
EWSR1-NR4A3 fusion
|
Soft Tissue Sarcoma
|
EWSR1-NR4A3 fusion
|
Soft Tissue Sarcoma
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
SMARCB1 deletion
|
Soft Tissue Sarcoma
|
SMARCB1 deletion
|
Soft Tissue Sarcoma
|
tazemetostat Sensitive: C3 – Early Trials
|
tazemetostat Sensitive: C3 – Early Trials
|
SS18-SSX fusion
|
Soft Tissue Sarcoma
|
SS18-SSX fusion
|
Soft Tissue Sarcoma
|
venetoclax + S63845 Sensitive: C3 – Early Trials
|
venetoclax + S63845 Sensitive: C3 – Early Trials
|
IFIH1 expression
|
Soft Tissue Sarcoma
|
IFIH1 expression
|
Soft Tissue Sarcoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CTSG expression
|
Soft Tissue Sarcoma
|
CTSG expression
|
Soft Tissue Sarcoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
STC2 expression
|
Soft Tissue Sarcoma
|
STC2 expression
|
Soft Tissue Sarcoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
SECTM1 expression
|
Soft Tissue Sarcoma
|
SECTM1 expression
|
Soft Tissue Sarcoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
LAG3 overexpression
|
Soft Tissue Sarcoma
|
LAG3 overexpression
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: C3 – Early Trials
|
trabectedin Sensitive: C3 – Early Trials
|
CTLA4 overexpression
|
Soft Tissue Sarcoma
|
CTLA4 overexpression
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: C3 – Early Trials
|
trabectedin Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
trabectedin Sensitive: C3 – Early Trials
|
trabectedin Sensitive: C3 – Early Trials
|
CDK4 amplification
|
Soft Tissue Sarcoma
|
CDK4 amplification
|
Soft Tissue Sarcoma
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
RB1 expression
|
Soft Tissue Sarcoma
|
RB1 expression
|
Soft Tissue Sarcoma
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
TFE3 rearrangement + MET expression
|
Soft Tissue Sarcoma
|
TFE3 rearrangement + MET expression
|
Soft Tissue Sarcoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
HMGA1 overexpression
|
Soft Tissue Sarcoma
|
HMGA1 overexpression
|
Soft Tissue Sarcoma
|
trabectedin Resistant: C3 – Early Trials
|
trabectedin Resistant: C3 – Early Trials
|
HDAC1 amplification
|
Soft Tissue Sarcoma
|
HDAC1 amplification
|
Soft Tissue Sarcoma
|
PD1 inhibitor + chidamide Sensitive: C3 – Early Trials
|
PD1 inhibitor + chidamide Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
CLDN6 positive
|
Soft Tissue Sarcoma
|
CLDN6 positive
|
Soft Tissue Sarcoma
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
DDR
|
Soft Tissue Sarcoma
|
DDR
|
Soft Tissue Sarcoma
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
MAD2L2 underexpression
|
Soft Tissue Sarcoma
|
MAD2L2 underexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
XRCC2 underexpression
|
Soft Tissue Sarcoma
|
XRCC2 underexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
RAD54L underexpression
|
Soft Tissue Sarcoma
|
RAD54L underexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
BLM underexpression
|
Soft Tissue Sarcoma
|
BLM underexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
APEX2 underexpression
|
Soft Tissue Sarcoma
|
APEX2 underexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
ATM overexpression
|
Soft Tissue Sarcoma
|
ATM overexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
SLFN11 overexpression
|
Soft Tissue Sarcoma
|
SLFN11 overexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
PIK3R1 overexpression
|
Soft Tissue Sarcoma
|
PIK3R1 overexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
CDKN2A overexpression
|
Soft Tissue Sarcoma
|
CDKN2A overexpression
|
Soft Tissue Sarcoma
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
olaparib + trabectedin Sensitive: C3 – Early Trials
|
COL1A1-PDGFB fusion
|
Soft Tissue Sarcoma
|
COL1A1-PDGFB fusion
|
Soft Tissue Sarcoma
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KANK1-NTRK2 fusion
|
Soft Tissue Sarcoma
|
KANK1-NTRK2 fusion
|
Soft Tissue Sarcoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
ERC1-ALK fusion
|
Soft Tissue Sarcoma
|
ERC1-ALK fusion
|
Soft Tissue Sarcoma
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
LMNA-NTRK1 fusion
|
Soft Tissue Sarcoma
|
LMNA-NTRK1 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
RANBP2-ALK fusion
|
Soft Tissue Sarcoma
|
RANBP2-ALK fusion
|
Soft Tissue Sarcoma
|
doxorubicin hydrochloride Resistant: C4 – Case Studies
|
doxorubicin hydrochloride Resistant: C4 – Case Studies
|
RANBP2-ALK fusion
|
Soft Tissue Sarcoma
|
RANBP2-ALK fusion
|
Soft Tissue Sarcoma
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
ATF1 overexpression
|
Soft Tissue Sarcoma
|
ATF1 overexpression
|
Soft Tissue Sarcoma
|
ruxolitinib Sensitive: C4 – Case Studies
|
ruxolitinib Sensitive: C4 – Case Studies
|
PDE4DIP-NTRK1 fusion
|
Soft Tissue Sarcoma
|
PDE4DIP-NTRK1 fusion
|
Soft Tissue Sarcoma
|
doxorubicin hydrochloride + ifosfamide Resistant: C4 – Case Studies
|
doxorubicin hydrochloride + ifosfamide Resistant: C4 – Case Studies
|
YWHAE-ROS1 fusion
|
Soft Tissue Sarcoma
|
YWHAE-ROS1 fusion
|
Soft Tissue Sarcoma
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
SQSTM1-NTRK1 fusion
|
Soft Tissue Sarcoma
|
SQSTM1-NTRK1 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
PDE4DIP-NTRK1 fusion
|
Soft Tissue Sarcoma
|
PDE4DIP-NTRK1 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
JAK1 overexpression
|
Soft Tissue Sarcoma
|
JAK1 overexpression
|
Soft Tissue Sarcoma
|
ruxolitinib Sensitive: C4 – Case Studies
|
ruxolitinib Sensitive: C4 – Case Studies
|
PIK3CA E542K
|
Soft Tissue Sarcoma
|
PIK3CA E542K
|
Soft Tissue Sarcoma
|
trametinib + pazopanib Sensitive: C4 – Case Studies
|
trametinib + pazopanib Sensitive: C4 – Case Studies
|
DCTN1-NTRK1 fusion
|
Soft Tissue Sarcoma
|
DCTN1-NTRK1 fusion
|
Soft Tissue Sarcoma
|
BAY 2731954 Resistant: C4 – Case Studies
|
BAY 2731954 Resistant: C4 – Case Studies
|
DCTN1-NTRK1 fusion
|
Soft Tissue Sarcoma
|
DCTN1-NTRK1 fusion
|
Soft Tissue Sarcoma
|
larotrectinib Resistant: C4 – Case Studies
|
larotrectinib Resistant: C4 – Case Studies
|
STRN-NTRK2 fusion + CDKN2B Deletion
|
Soft Tissue Sarcoma
|
STRN-NTRK2 fusion + CDKN2B Deletion
|
Soft Tissue Sarcoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
PD-L1 expression
|
Soft Tissue Sarcoma
|
camrelizumab Sensitive: C4 – Case Studies
|
camrelizumab Sensitive: C4 – Case Studies
|
